Search
Doxecitine
go.drugbank.com/drugs/DB02594ApprovedInvestigationalDoxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine. … This combination is the first and only approved treatment for Thymidine Kinase 2 deficiency.[L54613, L54618]
Synonyms: 1-(2-Deoxy-β-D-ribofuranosyl)cytosine, 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-Categories: Heterocyclic Compounds, 1-RingLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnLater Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008. … It gained approval by European Commission in March 2009.
Synonyms: (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphtholCategories: Heterocyclic Compounds, 1-RingPlasma protein fraction (human)
go.drugbank.com/drugs/DB13968ApprovedInvestigationalIt is also stated that no more than 1% of the total protein should be gamma globulin.[L2260] PPFh is a sterile, frozen solution of solvent/detergent treated human plasma. … [L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains some electrolytes such as sodium, potassium and chloride.[L2261]
Products: SANDOGLOBULINA 6 G, PLASMANATE INJECTION 5%Buformin
go.drugbank.com/drugs/DB04830ApprovedWithdrawnIt was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.
Categories: Drugs Used in DiabetesSynonyms: 1-ButylbiguanideMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections. … Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsProducts: Livtencity 200 mg Film Kaplı Tablet (112 (56'lık 2 şişe) Adet)Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalIt should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).
Categories: Guanylate Cyclase-C Agonist, Guanylyl Cyclase C AgonistsBeremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigational[L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion. … Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy.
Synonyms: B-VEC, Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Categories: Angiopoietin-like 3 Inhibitor, Angiopoietin-like 3 InhibitorsOnasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigationalmuscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. … [L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA